- Report
- January 2024
- 200 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- November 2023
- 115 Pages
United States
From €3625EUR$3,750USD£3,116GBP
- Report
- October 2022
- 270 Pages
Global
From €3625EUR$3,750USD£3,116GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2658EUR$2,750USD£2,285GBP
- Report
- September 2022
- 282 Pages
Global
From €9184EUR$9,500USD£7,894GBP
- Clinical Trials
- September 2021
- 60 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Drug Pipelines
- July 2018
- 27 Pages
Global
From €2417EUR$2,500USD£2,077GBP
- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1933EUR$2,000USD£1,662GBP
- Report
- April 2018
United States
From €7729EUR$7,995USD£6,643GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Drug Pipelines
- July 2018
- 503 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- February 2019
- 202 Pages
Global
From €5191EUR$5,370USD£4,462GBP
Abatacept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It works by blocking the activity of a molecule called CTLA-4, which is involved in the body's immune response. Abatacept is administered through an intravenous infusion or subcutaneous injection. It is used to reduce inflammation and pain associated with these conditions, as well as to slow down the progression of joint damage.
Abatacept is a relatively new drug, having been approved by the US Food and Drug Administration in 2005. It is one of several biologic drugs used to treat immune disorders, and is often used in combination with other medications.
Some companies in the Abatacept market include Bristol-Myers Squibb, AstraZeneca, and Pfizer. Show Less Read more
